Euan Walpole

Immune Checkpoint Inhibitors in Field Cancerization and Keratinocyte Cancer Prevention

Charlotte V. Cox, Susan D. Brown, Euan Walpole, Edwige Roy et autres

Importance: Therapies for individual keratinocyte carcinomas (KCs) do not prevent the onset of new KCs in a field of sun damage, and therefore the KC burden remains unchanged. Objective: To investigate the association of immune checkpoint inhibitors (ICIs) with changes in field …

au (code pays fourni par la source)

Prognostic markers could extend adjuvant immunotherapy to high-risk stage IB/IIA melanoma: A modeling study

Samuel Tan, N. Muller, Chenhao Zhou, Euan Walpole et autres

au (code pays fourni par la source)

P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours (GCTs).

Blossom Mak, Ben Tran, Farzana Pashankar, Danish Mazhar et autres

TPS524 Background: Bleomycin, etoposide, and cisplatin (BEP) given 3-weekly x 4 remains standard first-line chemotherapy for intermediate and poor-risk metastatic GCT. Accelerating standard chemotherapy regimens by shortening the cycle length to 2-weekly improved cure rates in other cancers. P3BEP is the first …

au, us, gb, nz (code pays fourni par la source)

Steroid Premedication and Monoclonal Antibody Therapy: Should We Reconsider?

Emma Karlsen, Euan Walpole, Fiona Simpson

OPINION STATEMENT: Monoclonal antibody (mAb) therapy is now considered a main component of cancer therapy in Australia. Although traditionally thought of as pure signalling inhibitors, a large proponent of these medications function through antibody-dependent cell-mediated cytotoxicity (ADCC). Currently, most protocols and institutional …

au (code pays fourni par la source)

P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs).

Danka Sinikovic Zebic, Ben Tran, Andrew Martin, Farzana Pashankar et autres

TPS5102 Background: Bleomycin, etoposide, and cisplatin (BEP) given 3-weekly x 4 remains standard 1st line chemotherapy for intermediate or poor risk metastatic GCT. Accelerating standard regimens by shortening the cycle length to 2-weekly improved cure rates in other cancers. P3BEP will determine …

au, us, gb (code pays fourni par la source)

Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy

Marjan Mojtabavi Naeini, Felicity Newell, Lauren G. Aoude, Vanessa Bonazzi et autres

Oesophageal adenocarcinoma is a poor prognosis cancer and the molecular features underpinning response to treatment remain unclear. We investigate whole genome, transcriptomic and methylation data from 115 oesophageal adenocarcinoma patients mostly from the DOCTOR phase II clinical trial (Australian New Zealand Clinical …

au (code pays fourni par la source)

Abstract OT2-10-05: HER2Pro: A Phase 1b dose de-escalation study of high dose prochlorperazine added to paclitaxel, trastuzumab and pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer

Teesha Downton, Emma Karlsen, Katharine Cuff, Euan Walpole et autres

Abstract HER2Pro: A Phase 1b dose de-escalation study of high dose prochlorperazine added to paclitaxel, trastuzumab and pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer Authors Teesha Downton1,2, Emma Karlsen1, Katharine Cuff3,4, Euan Walpole3,4, Fiona Simpson3,4, Elgene Lim1,2. Affiliations 1Garvan …

au (code pays fourni par la source)

The Q-IMPROvE (Queensland-IMplementation of PRecision Oncology in brEast cancer) pilot study

Amy E. McCart Reed, Therese McCurry, Georgina E. Hollway, Haidar Al-Saig et autres

Abstract Background The cancer genomics field has embraced the advent of precision oncology, and vast volumes of data have been mined for biomarkers of drug actionability. While some cancers, such as lung cancer, have detailed panels of actionable genomic biomarkers, sequencing panels …

au (code pays fourni par la source)

P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs).

Danka Sinikovic Zebic, Martin R. Stockler, Andrew Martin, Farzana Pashankar et autres

TPS431 Background: Bleomycin, etoposide, and cisplatin (BEP) given 3-weekly x 4 remains standard 1st line chemotherapy for intermediate or poor risk metastatic GCT. Accelerating standard regimens by shortening the cycle length to 2-weekly improved cure rates in other cancers. P3BEP will determine …

au, us, gb, nz (code pays fourni par la source)

Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy

Marjan Mojtabavi Naeini, Felicity Newell, Lauren G. Aoude, Vanessa Bonazzi et autres

Data Tables are the Supplementary Data for the paper: Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy by Naeini et al.

au (code pays fourni par la source)

HPV status represents dominant trait driving delineation of survival-associated gene co-expression networks in head and neck cancer

Ahmed M. Mehdi, Chenhao Zhou, Gavin Turrell, Euan Walpole et autres

Integration of high-dimensional tumor gene expression data with clinicopathological data can increase our understanding of disease diversity, enable retrospective patient stratification, and identify new potential biomarkers and therapeutic targets. Using a systems biology approach, we provide a holistic overview of gene co-expression …

au (code pays fourni par la source)

Development of a key performance indicator for breast cancer in Queensland, Australia

Euan Walpole, Philippa Youl, Julie Moore, Michelle Frances Morris et autres

PURPOSE: Using population-based data for women diagnosed with stage I-III breast cancer, our aim was to examine the impact of time to treatment completion on survival and to identify factors associated with treatment delay. METHODS: This retrospective study used clinical and treatment …

au (code pays fourni par la source)